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A B S T R A C T   
Introduction: Liposomal amphotericin B (L-AMB), a broad spectrum anti-fungicidal drug, is often administered to 
treat invasive fungal infections (IFIs). However, the most suitable time to initiate treatment in septic shock 
patients with IFI is unknown. 
Methods: Patients with septic shock treated with L-AMB were identified from the Japanese Diagnosis Procedure 
Combination national database and were stratified according to L-AMB treatment initiation either at septic shock 
onset (early L-AMB group) or after the onset (delayed L-AMB group) to determine their survival rates following 
septic shock onset and the shock cessation period. 
Results: We identified 141 patients administered L-AMB on the day of or after septic shock onset: 60 patients 
received early treatment, whereas 81 patients received delayed treatment. Survival rates after septic shock onset 
were higher in the early L-AMB group than in the delayed L-AMB group (4 weeks: 68.4% vs 57.9%, P = 0.197; 6 
weeks: 62.2% vs 44.5%, P = 0.061; 12 weeks: 43.4% vs 35.0%, P = 0.168, respectively). The septic shock 
cessation period was shorter in the early L-AMB group than in the delayed L-AMB group (7.0 ± 7.0 days vs 16.5 
± 15.4 days, P < 0.001), with a significant difference confirmed after adjusting for confounding factors with 
propensity score matching (7.1 ± 7.2 days vs 16.7 ± 14.0 days, P = 0.001). 
Conclusion: Early L-AMB administration at septic shock onset may be associated with early shock cessation.   
1. Introduction 
Invasive fungal infections (IFIs) frequently occur in immunocom-
promised patients and critically-ill patients and are associated with high 
rates of morbidity and mortality [1–6]. Identifying the appropriate time 
to start antifungal treatment for IFI patients is thus crucial to improving 
the prognosis. For example, in candidemia, a significant reduction in 
crude mortality was observed if antifungal medication was initiated 
within 24 h of the date of positive blood culture [7,8]. Furthermore, a 
trend toward reduced crude mortality has been reported with the initi-
ation of antifungal medication within 48 or 72 h of the onset of septic 
shock due to candidemia [9,10]. Conversely, prophylactic or empiric 
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antifungal administration has been reported to reduce the incidence of 
IFIs but not improve crude mortality [11,12]. Additionally, in patients 
with septic shock caused by candidemia, the time from positive blood 
cultures to the start of antifungal medication did not differ between the 
survival and death groups [13]. As a result, the appropriate timing of 
treatment initiation for septic shock patients with IFI remains unclear. 
Most clinical studies on the timing of antifungal drug initiation have 
been conducted in candidemia and only a few studies on empirical 
treatments have been performed. However, because the positive rate of 
fungal cultures, including blood cultures, is not high enough [14], 
empirical treatment is often used in actual clinical practice. Therefore, 
knowledge of the appropriate time to initiate empirical treatment with 
antifungal drugs is needed. 
Liposomal amphotericin B (L-AMB) has a broad anti-fungicidal 
spectrum that covers most clinically relevant yeasts and molds that 
cause mycoses, such as candidiasis, aspergillosis, cryptococcosis, and 
mucormycosis [15]. L-AMB is used as a first-line drug in critically-ill IFI 
patients with candidiasis, aspergillosis, and mucormycosis who exhibit 
resistance to other antifungal drugs [16]. Thus, we aimed to clarify the 
effect of L-AMB administration timing on the outcome of septic shock 
patients requiring IFI treatment. 
2. Patients and methods 
2.1. Ethics 
This study was conducted in accordance with the Declaration of 
Helsinki. The data herein were anonymously processed by the database 
provider (Medical Data Vision Co., Ltd) in accordance with the Act on 
the Protection of Personal Information of Japan and other related reg-
ulations. For the usage of unlinkable, de-identified data, ethical 
approval and informed consent were waived according to the Japanese 
Ethical Guidelines for Medical and Health Research Involving Human 
Subjects by the Ministry of Education, Culture, Sports, Science, and 
Technology, and the Ministry of Health, Labour, and Welfare of Japan. 
The study received ethical approval from Nagasaki University School of 
Medicine Research Ethics Committee (approval number 18033038-5). 
2.2. Study design and data source 
This retrospective study was conducted with administrative claims 
data obtained from an electronic medical information database (Medical 
Data Vision Co., Ltd), which contains diagnosis procedure combination 
(DPC) hospital data and medical fee reimbursement claims from 345 
facilities in Japan. Baseline patient information included age, sex, 
diagnosis, and comorbidities at admission, coded using the International 
Classification of Diseases, 10th Revision (ICD-10) codes. The database 
also contained all drug dosages and administration dates during hospi-
talization. All interventional procedures were decoded from the original 
Japanese codes. DPC is an administrative database containing inpatient 
information. Therefore, patient follow-up began on admission day and 
ended on discharge date, transferal to other hospitals, or death. 
2.3. Patient selection 
We identified patients administered L-AMB during hospitalization 
between April 2008 and January 2018. Patients with septic shock were 
defined as subjects treated with catecholamines. Septic shock onset was 
defined as the date of catecholamine treatment initiation. Patients that 
began L-AMB treatment on the day of or after septic shock onset and 
those administered carbapenems at septic shock onset were selected to 
avoid the effects that arise as confounders owing to antibiotics. Patients 
who met the following criteria were excluded: 1) <18 years old; 2) L- 
AMB daily dosing >6 mg/kg body weight; 3) <5 days of L-AMB treat-
ment duration; 4) L-AMB administration before septic shock onset; 5) 
began L-AMB treatment four weeks after septic shock onset; 6) no fungal 
infection tests such as culture, drug susceptibility tests of fungus, β-D- 
glucan, or antigens of Aspergillus, Candida, and Cryptococcus within 
seven days before the initiation of L-AMB administration; and 7) lacking 
required data, including body weight and outcome. The early L-AMB 
group included patients who initiated L-AMB treatment at septic shock 
onset, whereas the delayed group included patients who began treat-
ment on and after the day following septic shock onset. 
2.4. Variables and endpoints 
We evaluated patient characteristics, including age, sex, IFI disease 
name, and antifungal drugs administered before L-AMB treatment 
initiation. Comorbidities were evaluated using the Charlson comorbidity 
index (CCI) [17]. CCI has been widely used by researchers to measure 
case mix and burden of disease. It includes 17 conditions that have a 
major impact on survival and are defined by the ICD-10 codes [18]. A 
higher CCI depicts the presence of severe comorbidities. The presence of 
malignant tumor, neutropenia treated with granulocyte 
colony-stimulating factor (G-CSF), corticosteroid treatment (≥0.3 
mg/kg/day prednisolone conversion), diabetes treated with insulin, and 
T cell immunosuppressant therapy were assessed to evaluate the state of 
immunosuppression before and at septic shock onset. T cell immuno-
suppressant therapy was defined as treatment with calcineurins, anti--
TNFα inhibitors, anti-lymphocyte monoclonal antibodies, and purine 
and pyrimidine analogs the day of or within 90 days before septic shock 
onset [19]. The presence of a central venous (CV) catheter insertion and 
a history of gastrointestinal surgery were retrieved to evaluate the risk 
factors associated with the outcome of IFI treatment. Digestive tract 
surgery was defined as a surgery that incised the esophagus, stomach, 
duodenum, jejunum, ileum, cecum, appendix, colon, and rectum the day 
of or within 30 days before septic shock onset. The presence of in-
terventions, including intensive care unit (ICU) admission, renal 
replacement therapy (RRT), mechanical ventilation, and CV catheter 
replacement, was assessed to evaluate the state of patients before and at 
septic shock onset. However, CV catheter removal was not evaluated as 
this was not included in the claims data. Initiation of IFI therapy before 
the onset of septic shock as well as oral and injected antifungal drug 
treatment before the initiation of L-AMB therapy were assessed to 
evaluate previous experience with antifungal treatment. IFI treatment 
was defined as the time from initiation of intravenous injection treat-
ment with antifungal drugs to discontinuation, which was defined as an 
administration interval ≥2 days. This period includes the date of L-AMB 
therapy initiation. The attributes of clinicians were assessed to evaluate 
their experience with L-AMB dispensing or their capability to carry out 
patient management. Treatment departments were classified into four 
categories: hematology, which included clinicians with extensive 
experience in treating invasive pulmonary aspergillosis and pulmonary 
mucormycosis with L-AMB; internal departments, except the hematol-
ogy department; surgical department; and other departments (e.g., 
emergency medicine). L-AMB or catecholamine treatment duration was 
defined as the time from treatment initiation to discontinuation, where 
treatment discontinuation was defined as an administration interval ≥8 
or ≥2 days, respectively. Septic shock cessation was defined as cate-
cholamine treatment termination. The following endpoints were 
assessed: 1) survival rates at 4, 6, and 12 weeks after septic shock onset, 
and 2) septic shock cessation period. 
2.5. Statistical analysis 
The survival rates after septic shock onset or during septic shock 
treatment were calculated using the Kaplan-Meier method and statisti-
cally evaluated with the log-rank test. Propensity scores were calculated 
using a logistic regression model and the following covariates: 14 vari-
ables related to prognosis of patients with septic shock from a clinical 
perspective, and variables with a significant difference between the 
early and delayed L-AMB groups in patient characteristics. Variables 
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associated with prognosis in patients with septic shock included those 
related to antifungal treatment (timing of L-AMB treatment initiation, 
daily average dosing of L-AMB, history of antifungal drug administra-
tion before the initiation of L-AMB administration, initiation of IFI 
therapy before septic shock onset), patient characteristics (age, sex, CCI, 
presence of neutropenia with G-CSF administration, treatment with 
corticosteroid, and T cell immunosuppressants), interventions (ICU 
admission, CV catheter replacement, and RRT), and clinician’s attribute 
(hematology department). Using these propensity scores, early L-AMB 
cases were individually matched with delayed L-AMB cases at a 1-to-1 
ratio using the nearest matching method within a 0.1 caliper distance. 
After matching, a paired Student’s t-test was performed to compare the 
septic shock cessation period. Continuous variables were presented as 
the average ± standard deviation. Welch’s t-test was used to compare 
two groups for continuous variables, while the Fisher’s exact test was 
used for two categorical variables. 
3. Results 
3.1. Comparison of baseline characteristics 
In total, 6640 patients administered L-AMB were selected. There-
after, we identified 141 patients administered L-AMB on the day of or 
after septic shock onset: 60 patients received early L-AMB treatment at 
septic shock onset (early L-AMB group) whereas 81 patients received 
delayed L-AMB treatment on and after the day following septic shock 
onset (delayed L-AMB group) (Fig. 1). 
The characteristics of patients in both groups are shown in Table 1. 
CCI and the proportion of immunosuppressed patients treated with 
corticosteroids or T cell immunosuppressants, patients with aspergil-
losis, and patients treated in the hematology department were higher in 
the early L-AMB group than the delayed L-AMB group. However, older 
patients, those requiring RRT, and those treated in the surgical depart-
ment were more frequent in the delayed L-AMB group than the early L- 
AMB group. In the delayed L-AMB group, L-AMB treatment was initiated 
at 5.6 ± 6.1 days from septic shock onset. In both groups, over 60% of 
patients switched to L-AMB from other antifungal drugs, the majority of 
which used echinocandins, such as micafungin and caspofungin, before 
L-AMB treatment initiation. The proportion of patients treated with 
voriconazole or itraconazole was higher in the early L-AMB group than 
the delayed L-AMB group (30% vs 15%, P = 0.038). This might be partly 
attributed to the higher presence of patients with aspergillosis in the 
early L-AMB group. In total, 35% of patients initiated IFI treatment 
before septic shock onset (early L-AMB group 47% of subjects; delayed 
L-AMB group 26% of subjects; P = 0.013). For patients administered IFI 
treatment before septic shock onset, no difference in the duration from 
IFI treatment initiation to septic shock was found between those in the 
early (12.9 ± 12.7 days, N = 28) and delayed L-AMB groups (9.7 ± 16.3 
days, N = 21, P = 0.478). 
3.2. Comparison of survival rates after septic shock onset 
Survival rates at 4 weeks (68.4% vs 57.9%, P = 0.197), 6 weeks 
(62.2% vs 44.5%, P = 0.061), and 12 weeks (43.4% vs 35.0%, P =
0.168) after septic shock onset were higher in the early L-AMB group 
than the delayed L-AMB group, albeit without statistical significance 
(Fig. 2; Table 2). Sensitivity analysis revealed that survival rates did not 
significantly differ between patients whose L-AMB treatment was initi-
ated within a day after septic shock onset and those whose treatment 
was initiated on and after two days following the onset; and patients 
whose L-AMB treatment was initiated within the two days after septic 
shock onset and those whose treatment was initiated on and after three 
days following the onset (Supplementary Table 1). 
3.3. Comparison of septic shock cessation period 
The septic shock cessation period was shorter in the early L-AMB 
group (7.0 ± 7.0 days, median: 4.5 days) than the delayed L-AMB group 
(16.5 ± 15.4 days, median: 12.0 days, P < 0.001) (Table 3). To balance 
the patient characteristics, propensity score matching was performed 
according to a multiple logistic regression model using 14 covariates 
related to prognosis in patients with septic shock and 3 covariates with a 
significant difference between the early and delayed L-AMB groups in 
patient characteristics (treatment with azoles for aspergillosis before the 
Fig. 1. Flow chart for patient selection. 
L-AMB, liposomal-amphotericin B. 
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initiation of L-AMB therapy, surgical department, and aspergillosis) 
(Table 1). Following propensity score matching, no difference was 
observed in patient characteristics between the early and delayed L- 
AMB groups (Supplementary Table 2). We confirmed shorter septic 
shock cessation period in the early L-AMB group (7.1 ± 7.2 days, me-
dian: 3.0 days, N = 36) than in the delayed L-AMB group (16.7 ± 14.0 
days, median: 12.5 days, N = 36; P = 0.001) (Table 3). Sensitivity 
analysis demonstrated that the septic shock cessation period was 
significantly shorter in patients administered early L-AMB treatment 
within a day after septic shock onset or within two days after the onset 
than in patients administered late treatment (Supplementary Table 3). 
4. Discussion 
Herein, we found early initiation of L-AMB treatment at septic shock 
onset was associated with short septic shock cessation period. However, 
this association may not imply causation, because patients with shock 
caused by non-IFI causes, such as bacterial infections or hypovolemic 
shock, might be included in subjects analyzed in the study. Importantly, 
the timing of L-AMB treatment was not associated with mortality during 
septic shock treatment: survival rates during septic shock treatment 
were similar between the early and delayed L-AMB groups (Fig. S1). This 
finding may imply that a risk of mortality during septic shock treatment 
increases regardless of the timing of L-AMB administration as duration 
of septic shock treatment is prolonged. Therefore, early L-AMB treat-
ment at septic shock onset, which is associated with short septic shock 
cessation period, as a consequence might be linked to decreased mor-
tality during septic shock treatment. 
Patients analyzed in this study may include patients with various IFIs 
and those without IFIs. However, cases that were not tested for fungus 
were excluded, and patients without the possibility of IFI were not 
included. Several studies have revealed that early initiation of antifungal 
drug administration improves the outcome of patients with candidiasis 
[7,8]. Our findings demonstrate that the timing of L-AMB administration 
may affect the prognosis of septic shock in a population with confirmed 
cases and empirical situations. The impact of such results on clinical 
practice is significant as the diagnosis cannot be confirmed in clinical 
practice in many situations. 
Because the backgrounds of patients in the early and delayed L-AMB 
groups differed markedly in this study, we carefully conducted pro-
pensity score matching to adjust for confounding factors. For example, 
the proportion of patients treated in the hematology department was 
higher in the early L-AMB group, whereas the proportion of patients 
treated in the surgical department was higher in the delayed L-AMB 
group. We were mainly concerned that the difference in the overall 
management ability for IFIs between hematologists accustomed to 
treating IFIs and surgeons unfamiliar with IFIs may have influenced the 
difference in the septic shock cessation period between the two groups. 
Therefore, we calculated propensity scores using the covariates related 
to the attribute (hematology), immunosuppression state (e.g., neu-
tropenia treated with G-CSF), and risk factors of poor treatment outcome 
of candidiasis (e.g., CV catheter replacement). Collectively, we revealed 
the association between early L-AMB initiation and short septic shock 
cessation period. 
However, the difference in survival rates four weeks after septic 
shock onset did not reach statistical significance between the groups. 
These results align with prior findings: crude mortality at 30 days 
following positive blood culture is associated with age, RRT, intubation, 
and primary source, but not with prompt proper antifungal treatment 
[10]. As the septic shock cessation period was 9 days (median) in all 
patients, septic shock might have already improved in many patients 
within four weeks after septic shock onset. However, these patients may 
have died from primary diseases that were unaffected by L-AMB treat-
ment, as many patients with IFI have a serious background illness and 
often have a poor prognosis. 
If early L-AMB administration improves the prognosis of IFI-induced 
Table 1 
Characteristics of septic shock patients administered early or delayed L-AMB.  
Patient characteristics Overall 













70.7 ± 13.0 0.020 
Sex, male (%) 90 (64%) 37 (62%) 53 (65%) 0.724 
Preexisting comorbid conditions 
CCI 3.7 ± 3.1 4.4 ± 3.3 3.2 ± 2.9 0.035 
Malignant tumor (%) 75 (53%) 36 (60%) 39 (48%) 0.176 
G-CSF treatment for 
neutropenia (%) 
29 (21%) 16 (27%) 13 (16%) 0.143 
Corticosteroid (≥0.3 mg/kg/ 
day Prednisolone) (%) 
62 (44%) 33 (55%) 29 (36%) 0.027 
T cell immunosuppressants 35 (25%) 21 (35%) 14 (17%) 0.019 
Diabetes mellitus with insulin 
treatment (%) 
32 (23%) 12 (20%) 20 (25%) 0.548 
Gastrointestinal surgery 
within 30 days (%) 
12 (9%) 2 (3%) 10 (12%) 0.071 
CV catheter (%) 100 
(71%) 
47 (78%) 53 (65%) 0.133 
Interventions 
ICU admission (%) 39 (28%) 14 (23%) 25 (31%) 0.348 
Renal replacement therapy 
(%) 
43 (30%) 12 (20%) 31 (38%) 0.026 
Mechanical ventilation (%) 56 (40%) 24 (40%) 32 (40%) 1.000 
CV catheter replacement 
within the following day (%) 
22 (16%) 11 (18%) 11 (14%) 0.487 
L-AMB administration 
Average daily dosing (mg/kg) 2.9 ± 1.0 2.9 ± 1.0 2.9 ± 1.0 0.919 




13.8 ± 11.2 0.081 
L-AMB administration 
initiation after the onset of 
septic shock (days) 
3.2 ± 5.4 0.0 ± 0.0 5.6 ± 6.1 NA 
Initiation of IFI therapy before 
the onset of septic shocka 
49 (35%) 28 (47%) 21 (26%) 0.013 
Antifungal drug treatment before the initiation of L-AMB therapy (%)b 
Overall 90 (64%) 39 (65%) 51 (63%) 0.860 
Echinocandin (micafungin, 
caspofungin) 
69 (49%) 27 (45%) 42 (52%) 0.496 
Azole not for Aspergillosis 
(fluconazole) 
17 (12%) 8 (13%) 9 (11%) 0.795 
Azole for Aspergillosis 
(itraconazole, voriconazole) 
30 (21%) 18 (30%) 12 (15%) 0.038 
Treatment department (%) 
Hematology 46 (33%) 27 (45%) 19 (23%) 0.011 
The internal department 
(except for Hematology) 
63 (45%) 26 (43%) 37 (46%) 0.864 
The surgical department 27 (19%) 5 (8%) 22 (27%) 0.005 
Othersc 2 (1%) 0 (0%) 2 (2%) 0.508 
Unknown 3 (2%) 2 (3%) 1 (1%) 0.575 
Diagnosis (%) 
Aspergillosis 31 (22%) 19 (32%) 12 (15%) 0.023 
Candidiasis 17 (12%) 9 (15%) 8 (10%) 0.436 
Othersd 29 (21%) 9 (15%) 20 (25%) 0.207 
Unknowne 65 (46%) 24 (40%) 41 (51%) 0.235 
Abbreviations: CCI, Charlson comorbidity index; CV, central venous; G-CSF, 
granulocyte-colony stimulating factor; ICU, intensive care unit; L-AMB, 
liposomal-amphotericin B, NA, not analyzed. 
Categorical variables were presented as frequencies and proportions (%), while 
continuous variables were expressed as mean ± standard deviation. Welch’s t- 
test was employed to compare two groups for continuous variables, while 
Fisher’s exact test was used for two categorical variables. 
a IFI treatment was defined as the time from initiation of intravenous injection 
treatment with antifungal drugs to discontinuation, which was defined as an 
administration interval of ≥2 days. This period included the date of L-AMB 
therapy initiation. 
b Oral and injection antifungal drugs were evaluated. 
c Other treatment department included anesthesiology and emergency 
medicine. 
d Other diagnoses included cryptococcosis, zygomycosis, coccidioidomycosis, 
blastomycosis, maduramycosis, and unclassified or unspecified mycoses. 
e Unknown diagnosis included patients without any mycosis diagnosis and 
those with neutropenia. 
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septic shock, early administration of other antifungal drugs could also 
improve the prognosis. In the delayed L-AMB group, although 38% (31/ 
81) of patients were treated with antifungal drugs except for L-AMB at 
septic shock onset, the septic shock cessation period in those patients 
(19.1 ± 17.3 days) was longer than in patients administered L-AMB at 
septic shock onset (7.0 ± 7.0 days, P < 0.001). These results suggest that 
early L-AMB initiation may be particularly important. 
Sixty four percent of patients were switched from other antifungal 
drugs to L-AMB, suggesting that a switch to L-AMB is effective even for 
septic shock antifungal treatment. This switching might be partly 
attributed to insufficient treatment outcomes of other antifungal drugs. 
Echinocandin-resistant Candida has been reported [20]; echinocandins 
are not used as first-line drugs against invasive pulmonary aspergillosis 
and are ineffective for pulmonary mucormycosis [21]. Therefore, early 
L-AMB initiation might be beneficial, especially for septic shock patients 
whose target fungus has not been identified or in patients infected with a 
drug susceptibility-unconfirmed fungus. 
Clinicians in the hematology department, but not the surgical 
department, may initiate L-AMB administration at septic shock onset, 
suggesting that sufficient experience with L-AMB treatment is required 
for prompt treatment initiation. Both hematologists and physicians who 
are familiar with the use of L-AMB are infectious disease specialists. In 
cases of septic shock with possible IFI, physician intervention for an 
Fig. 2. Kaplan-Meier survival curve for septic shock patients administered early or delayed L-AMB. 
L-AMB, liposomal-amphotericin B. 
Table 2 
Survival rates for patients administered early or delayed L-AMB after septic 
shock onset.  
Weeks after the onset of 
septic shock 
Survival rates (%, 95% CI) P- 
value 
Early L-AMB (N =
60) 
Delayed L-AMB (N =
81) 
4 weeks 68.4% 
(57.2–81.7%) 
57.9% (48.0–69.7%) 0.197 
6 weeks 62.2% 
(50.5–76.6%) 
44.5% (34.8–57.0%) 0.061 
12 weeks 43.4% 
(30.7–61.2%) 
35.0% (25.1–48.7%) 0.168 
Abbreviations: CI, confidence interval; L-AMB, liposomal-amphotericin B. 
Table 3 
Septic shock cessation period for patients administered early or delayed L-AMB 
before and after propensity score matching.   































Median 4.5 12.0  3.0 12.5  
Abbreviations: AVE, average; L-AMB, liposomal-amphotericin B; SD, standard 
deviation. 
The septic shock cessation period was presented as average ± standard devia-
tion. Welch’s t-test was used to compare two groups without adjustment, while 
paired Student’s t-tests were performed to compare two groups after propensity 
score matching. 
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infectious disease on the day of onset may improve prognosis. 
This study had several limitations. First, several data could not be 
obtained from the database. Indicators of infectious severity, such as 
acute physiology and chronic health evaluation (APACHE) II and 
sequential organ failure assessment (SOFA), were not evaluated because 
respiratory or cardiovascular parameters were not included in the 
database. Alternatively, we opted to calculate the propensity score using 
variables related to ICU admission, RRT, and detailed patient charac-
teristics to validate the reliability of our results. As source control was 
not evaluated using CV catheter removal, we opted to evaluate 
replacement instead of CV catheter removal. As the results of fungal 
infection tests or blood culture tests could not be obtained, we could not 
distinguish definitive or presumed antifungal infection or could not 
exclude patients with blood stream infections caused by bacteria to 
avoid the influence of bacterial infections on outcome. Second, owing to 
the retrospective nature of this analysis, prospective studies are required 
to verify the results. A retrospective analysis might be suitable for 
evaluating the efficacy of early L-AMB initiation in septic shock patients 
owing to the difficulty involved in conducting a prospective study. 
Finally, because a comparative study with non-L-AMB treatment cases 
was not carried out, the characteristics of septic shock cases that should 
be treated with L-AMB were not captured. Further studies are needed to 
further identify patients requiring L-AMB treatment. 
In conclusion, early L-AMB administration at septic shock onset may 
be associated with early shock cessation. 
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